Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Epi(geneti)c makeover: boosting anti-PD-1 in HL

Paul J. Bröckelmann

Blood (2024) 144 (18): 1850–1852.

https://doi.org/10.1182/blood.2024026162

Published: 2024

Journal Articles

Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment

Nicole Seifert, Sarah Reinke, Johanna Grund, Berit Müller-Meinhard, Andreas Engert, Peter Borchmann, Paul J Bröckelmann, Michael Altenbuchinger, Wolfram Klapper

Blood (2023) 142 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2023-186527

Published: 2023

Journal Articles

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Paul J Bröckelmann, Horst Müller, Sarah Gillessen, Anne Sophie Jacob, Jesko Momotow, Carla Damaschin, Justin Ferdinandus, Xiaoqin Yang, Michael Fuchs, Carsten Kobe, Hans Theodor Eich, Andreas Engert, Peter Borchmann, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2023-188622

Published: 2023

Journal Articles

Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Peter Herhaus, Julia Meissner, Karolin Trautmann-Grill, Horst Müller, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Karolin Behringer

Blood (2023) 142 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2023-189250

Published: 2023

Journal Articles

Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Peter Herhaus, Julia Meissner, Karolin Trautmann-Grill, Horst Müller, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Karolin Behringer

Blood (2023) 142 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2023-188734

Published: 2023

Journal Articles

AXL-erating mantle cell lymphoma treatment

Paul J. Bröckelmann

Blood (2023) 142 (17): 1411–1412.

https://doi.org/10.1182/blood.2023021455

Published: 2023

Journal Articles

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow

Blood (2022) 140 (Supplement 1): 1753–1755.

https://doi.org/10.1182/blood-2022-168846

Published: 2022

Journal Articles

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Jan-Michel Heger, Claus Moritz Graef, Philipp Falderbaum, Philipp Gödel, Hyatt Balke-Want, Florian Simon, Noëlle Sieg, Jan-Hendrik Naendrup, Marie Anne-Catherine Neumann, Sarah Gillessen, Paul J Bröckelmann, Dennis A. Eichenauer, Peter Borchmann, Bastian Von Tresckow

Blood (2021) 138 (Supplement 1): 2531.

https://doi.org/10.1182/blood-2021-145283

Published: 2021

Journal Articles

Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Blood (2021) 138 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2021-153200

Published: 2021

Journal Articles

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Blood (2020) 136 (25): 2851–2863.

https://doi.org/10.1182/blood.2020008553

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138413

Published: 2020

Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Blood (2019) 134 (Supplement_1): 236.

https://doi.org/10.1182/blood-2019-122406

Published: 2019

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD

Blood (2019) 134 (Supplement_1): 1547.

https://doi.org/10.1182/blood-2019-124351

Published: 2019

Journal Articles

Balancing risk and benefit in early-stage classical Hodgkin lymphoma

Paul J. Bröckelmann, Stephanie Sasse, Andreas Engert

Blood (2018) 131 (15): 1666–1678.

https://doi.org/10.1182/blood-2017-10-772665

Published: 2018

Journal Articles

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann

Blood (2016) 127 (18): 2189–2192.

https://doi.org/10.1182/blood-2015-11-681064

Published: 2016

Journal Articles

Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)

Paul J Bröckelmann, MD, Horst Müller, PhD, Olivier Casasnovas, MD, Martin Hutchings, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Craig Moskowitz, MD, Andreas Engert, MD

Blood (2015) 126 (23): 1978.

https://doi.org/10.1182/blood.V126.23.1978.1978

Published: 2015

NARROW

Epi(geneti)c makeover: boosting anti-PD-1 in HL

Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial

AXL-erating mantle cell lymphoma treatment

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Balancing risk and benefit in early-stage classical Hodgkin lymphoma

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only